Aspects of androgen replacement therapy for the treatment of hypogonadism in men with diabetes and metabolic syndrome.
https://doi.org/10.14341/omet2015111-14
Abstract
The article presents the results of studies of efficacy and safety of androgen therapy for hypogonadism, metabolic syndrome and type 2
diabetes mellitus in men. In the study was used testosterone undecanoate therapy which causes reduction of obesity, a decrease in the
severity of the other components of the metabolic syndrome, improving glycemic profile without significant side effects. Nevertheless,
this therapy requires monitoring and management for risk factors.
About the Authors
Роман Роживанов
Endocrinology Research Centre
Russian Federation
Russian Federation
Юлия Яшина
Endocrinology Research Centre
Russian Federation
endocrinologist
Russian Federation
endocrinologist
References
1. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. The Aging Male. 2009;12(1):5-12. doi: 10.1080/13685530802389628
2. Haider A, Yassin A, Doros G, Saad F. Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes. International Journal of Endocrinology. 2014;2014:1-15. doi: 10.1155/2014/683515
3. Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study. Obesity Research & Clinical Practice. 2014;8(4):e339-e49. doi: 10.1016/j.orcp.2013.10.005
4. Francomano D, Lenzi A, Aversa A. Effects of Five-Year Treatment with Testosterone Undecanoate on Metabolic and Hormonal Parameters in Ageing Men with Metabolic Syndrome. International Journal of Endocrinology. 2014;2014:1-9. doi: 10.1155/2014/527470
5. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity. 2013;21(10):1975-81. doi: 10.1002/oby.20407
6. Ganesh HK, Vijaya Sarathi HA, George J, Shivane VK, Bandgar T, Menon PS, et al. Prevalence of Hypogonadism in Patients with Type 2 Diabetes Mellitus in an Asian Indian Study Group. Endocrine Practice. 2009;15(6):513-20. doi: 10.4158/ep09035.orr
7. Mirzaei MR, Amini M, Aminorroaya A. The prevalence of hypogonadism in diabetic men in Isfahan Endocrine and Metabolism Research Center, Isfahan, Iran. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2012;17(7):602..
8. Al Hayek A, Ajlouni K, Khader Y, Jafal S, Khawaja N, Robert A. Prevalence of low testosterone levels in men with type 2 diabetes mellitus: a cross-sectional study. Journal of Family and Community Medicine. 2013;20(3):179. doi: 10.4103/2230-8229.122006
9. Dhindsa S, Miller MG, McWhirter CL, Mager DE, Ghanim H, Chaudhuri A, et al. Testosterone Concentrations in Diabetic and Nondiabetic Obese Men. Diabetes Care. 2010;33(6):1186-92. doi: 10.2337/dc09-1649
10. Farrell JB, Deshmukh A, Baghaie AA. Low Testosterone and the Association With Type 2 Diabetes. The Diabetes Educator. 2008;34(5):799-806. doi: 10.1177/0145721708323100
11. Traish AM, Saad F, Guay A. The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance. Journal of Andrology. 2008;30(1):23-32. doi: 10.2164/jandrol.108.005751
12. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nature Reviews Endocrinology. 2009;5(12):673-81. doi: 10.1038/nrendo.2009.212
13. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30(4):911-7. doi: 10.2337/dc06-1426
14. Randeva Harpal S, Ho C-H, Yu H-J, Wang C-Y, Jaw F-S, Hsieh J-T, et al. Prediabetes Is Associated with an Increased Risk of Testosterone Deficiency, Independent of Obesity and Metabolic Syndrome. PLoS ONE. 2013;8(9):e74173. doi: 10.1371/journal.pone.0074173
15. G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab. Male Hypogonadism. European Association of Urology.2015
16. Моргунов Л. Ю. Коррекция андрогенного дефицита у пациентов с сахарным диабетом 2 типа препаратами тестостерона //Андрология и генитальная хирургия. – 2007. – Т. 2. – С. 25-29 [Morgunov L. Korrektsiya androgennogo defitsita u patsientov s sakharnym diabetom 2 tipa preparatami testosterona. Andrologiya i genital'naya khirurgiya. 2007;2:25-9.].
17. Gianatti EJ, Dupuis P, Hoermann R, Strauss BJ, Wentworth JM, Zajac JD, Grossmann M. Еffect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014 Aug;37(8):2098-107.
18. Kapoor D. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology. 2006;154(6):899-906. doi: 10.1530/eje.1.02166
19. Heufelder А, Gooren L, Bunck M, Saad F. Testosterone Treatment Enhances the Favorable Effects of Exercise and Diet on Inflammation, Metabolism and Coagulation Markers in Hypogonadal Men with the Metabolic Syndrome. Presented at The Endocrine Society Annual Meeting; 2007 June 2-5; Canada, Toronto. ENDO Abstracts 2007; OR35-2.
20. Heufelder А, Gooren L, Bunck M, Saad F. Treatment with Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Hypogonadal Men with Newly Diagnosed Type 2 Diabetes. Presented at The Endocrine Society Annual Meeting; 2007 June 2-5; Canada, Toronto. ENDO Abstracts 2007; P2-272.
21. Роживанов Р. В. Синдром гипогонадизма у мужчин // Ожирение и метаболизм. 2014; 2. С. 30-34. [Rozhivanov RV. Syndrome of hypogonadism in males. Obesity and metabolism. 2014;11(2):30-34]. doi:10.14341/omet2014230-34
Review
For citations:
, Aspects of androgen replacement therapy for the treatment of hypogonadism in men with diabetes and metabolic syndrome. Obesity and metabolism. 2015;12(1):11-14. (In Russ.) https://doi.org/10.14341/omet2015111-14
Views:
594
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
